Federal Supply Schedule V797D60724
Award Date
9/30/16
Last Date to Order
9/14/23
Federal Agency
Veterans Integrated Service Network 12
Awardee
Genentech Usa, Inc.
Ultimate Awardee
Not listed
NAICS Category
325412 - Pharmaceutical Preparation Manufacturing
PSC Category
6505 - Drugs And Biologicals
Federal Contract Vehicle
Pricing Type
Fixed Price with Economic Price Adjustment
Legislative Mandate
Not listed
National Interest Action
None
Award Type
Multiple
Primary Consortia Member
Not listed
Similar IDVs
This federal contract indefinite delivery vehicle (IDV) is a $4.9 billion Federal Supply Schedule (FSS) awarded by the Department of Veterans Affairs (VA) to the prime contractor Genentech USA, Inc., a foreign-owned, for-profit pharmaceutical manufacturer. The contract covers a wide range of drugs, pharmaceuticals, and hematology-related products under the FSS-61-IB schedule. The IDV has facilitated several delivery orders, including a $45.1 million firm fixed-price contract with the Office of...
This indefinite delivery contract, awarded by the Defense Logistics Agency (DLA) to Genentech USA, Inc., a foreign-owned, for-profit pharmaceutical manufacturer, is focused on the procurement of critical medical supplies and pharmaceuticals to support the Department of Defense's global health logistics network. The $27,898,886.92 single-award contract has an ultimate completion date of May 21, 2031 and does not utilize any set-aside designations. Under this vehicle, Genentech has received...
The federal contract IDV award is a Federal Supply Schedule (FSS) contract with the Department of Veterans Affairs (VA) awarded to Regeneron Pharmaceuticals Inc., a for-profit pharmaceutical manufacturer. The contract, valued at up to $2,260,000,000, is for the provision of drugs, pharmaceuticals, and hematology-related products under the FSS-61-IB schedule. Task orders and blanket purchase agreements (BPAs) have been issued under this IDV to procure the drug EVKEEZA. A $148,228.56 delivery...
The Federal Supply Schedule (FSS) contract identified as 36F79720D0225 was awarded by the U.S. Department of Veterans Affairs (VA) to Novartis Gene Therapies Inc. on September 15, 2020. This multiple-award, indefinite delivery vehicle (IDV) contract is under the Pharmaceuticals and Drugs (FSS-61-IB) category, with a total ceiling value of $6,000,000,000 and a period of performance extending until September 14, 2026. The purpose of this contract is to provide the VA with a broad range of...
This Blanket Purchase Agreement was awarded by the Department of Veterans Affairs National Acquisition Center to Genentech USA, Inc. for the procurement of Evrysdi. The BPA has a potential value of $1 million and a period of performance from March 12, 2021 through September 14, 2023, with four one-year option periods. The BPA was established against the Pharmaceuticals and Drugs GSA Schedule and provides a contracting vehicle for ordering Evrysdi to treat spinal muscular atrophy. Spinal muscular...
The U.S. Department of Veterans Affairs (VA) has awarded Novartis Pharmaceuticals Corporation, a foreign-owned pharmaceutical manufacturer, a $5.4 billion Federal Supply Schedule (FSS) contract for Pharmaceuticals and Drugs (FSS-61-IB). This comprehensive IDV contract, which runs through August 2026, provides the VA with access to Novartis' portfolio of specialized medical treatments, including cancer therapies and advanced pharmaceuticals. Under this FSS contract, the VA has issued multiple...
Genzyme Corporation, doing business as Sanofi Genzyme, has been awarded a $659 million multiple-award Federal Supply Schedule (FSS-61-IB) contract by the Department of Veterans Affairs (VA) Veterans Health Administration (VHA) to provide pharmaceuticals and drugs. This IDV allows the VHA to issue delivery orders for a broad range of drug products from Genzyme's portfolio over a 5-year period to support healthcare programs for veterans. Genzyme has also been awarded a $4 million single-award...
This Blanket Purchase Agreement (BPA) awarded by the National Acquisition Center, a civilian agency of the U.S. federal government, to Genentech USA, Inc. is for the procurement of the pharmaceutical product Evrysdi. Evrysdi is a treatment for spinal muscular atrophy, a rare and severe genetic disease. The single-award BPA has a ceiling value of $1,725,140.20 and a period of performance ending on September 21, 2025. As a prime contractor, Genentech USA, Inc., a foreign-owned, for-profit...
This federal contract IDV is a Multiple Award Federal Supply Schedule (FSS) contract awarded by the Department of Veterans Affairs (VA) to Biogen U.S. Corporation, a pharmaceutical and biotechnology company. The contract has a ceiling value of $2,210,000,000 and a period of performance through September 14, 2026. Biogen has been awarded multiple firm-fixed-price delivery orders against this FSS contract to supply specialized pharmaceutical products to the VA, primarily through its Veterans...
This Federal Supply Schedule contract (Contract ID: 36F79720D0177) was awarded by the U.S. Department of Veterans Affairs (VA) to BeiGene USA, Inc. on August 1, 2020. The contract has a ceiling value of $700,000.00 and a period of performance through April 30, 2026. The contract is for the procurement of drugs, pharmaceuticals, and hematology-related products under the Pharmaceuticals and Drugs (FSS-61-IB) Federal Supply Schedule. As a multiple award schedule, this contract allows the VA to...
Name | Description | Awardee | Potential Value (Click to sort descending) | Award Date (Click to sort descending) | Last Date To Order (Click to sort descending) | Updated At (Click to sort descending) |
|---|---|---|---|---|---|---|
V797D60724-36E79721A0011 | Genentech Usa, Inc. | $1.0m | 3/12/21 | 9/14/23 | 9/14/23 |
Name | Description | Awardee | Potential Value (Click to sort descending) | Award Date (Click to sort descending) | Completion Date (Click to sort descending) | Updated At (Click to sort descending) |
|---|---|---|---|---|---|---|
Delivery Order V797D60724-75A50322F80028 | Genentech Usa, Inc. | $60.0m | 9/14/22 | 3/31/25 | 11/25/24 |